Fig. 2: PML-RARα inhibits glycolysis via AKT degradation. | Leukemia

Fig. 2: PML-RARα inhibits glycolysis via AKT degradation.

From: PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias

Fig. 2

A HK2, PKM2 and PFKP protein expression were analyzed in primary blasts obtained from APL and AML patients, and normal bone marrow cells (NBM). The numbers at the bottom of the western blot identify the patients described in Supplementary Table-S1. B Effects of 1 µM ATO treatment for 4 h in combination or not with 1 µM AKT inhibitor (Inhibitor VIII) for 30 min on the glycolytic activity in Fresh blasts from one APL patient (n° 8, Supplementary Table-S1) and C NB4 cells. Histograms represent basal glycolysis measured with the XF Glycolytic rate assay from two independent replicates. D Western blot detecting PML::RARα, AKT and p-AKT308 protein expression levels in (left) fresh blasts from an APL patient (n° 8, Supplementary Table-S1), (right) NB4 cells undergoing the treatments reported above. Protein values were analyzed by densitometric scanning and reported in the histogram after normalization with β-actin. Statistical analysis was performed using the Student’s t-test, ** p ≤ 0.005.

Back to article page